SCHEMBL1663422

SCHEMBL1663422

CN(C)c1ccc(C(=O)Nc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 2/20 0.67
MAPT P10636 7/20 0.66
ALDH1A1 P00352 5/20 0.66
MCL1 Q07820 4/20 0.66
KDM4E B2RXH2 3/20 0.66
LMNA P02545 3/20 0.66
HSD17B10 Q99714 2/20 0.66
TP53 P04637 1/20 0.66
KCNK3 O14649 2/20 0.65
MITF O75030 1/20 0.62
RAB9A P51151 5/20 0.61
TSHR P16473 1/20 0.61
FFAR1 O14842 1/20 0.60
NAMPT P43490 2/20 0.58
NPC1 O15118 5/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
POLB P06746 1/20 0.57
MAPK1 P28482 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7713301 0.91 MAPT (0.71) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL1663761 0.88 MAPT (0.68) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL1664367 0.88 MAPT (0.68) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL3638309 0.88 KCNK3 (0.82) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL5982606 0.88 KCNK3 (0.77) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL8770238 0.88 MAPT (0.68) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL30828562 0.88 HDAC1 (0.69) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL15482259 0.86 HDAC6 (0.72) P4HTMMAPTALDH1A1MCL1KDM4E
SCHEMBL8769917 0.86 RAB9A (0.76) P4HTMMAPTALDH1A1MCL1KDM4E
Iodide SCHEMBL30758605 0.86 KCNK3 (0.74) P4HTMMAPTALDH1A1MCL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
CN-102656141-B Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof LIGAND PHARMACEUTICALS INC. (US) 2016-04-06 CN disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
EP-2642994-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS Ligand Pharmaceuticals Incorporated (US) 2013-10-02 EP disclosed
CN-103282034-A Use of hematopoietic growth factor mimetics LIGAND PHARM INC 2013-09-04 CN disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
CN-102656141-A Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARM INC 2012-09-05 CN disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed
WO-1992019208-A1 N-PHENYL-BENZAMIDES PROVIDING PROTECTION FROM THE HARMFUL EFFECTS OF ULTRAVIOLET LIGHT BAUDET PIERRE (CH) 1992-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL P4HTM 324/4885MAPT 4622/4885ALDH1A1 3228/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF P4HTM 770/4885MAPT 4411/4885ALDH1A1 2736/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF P4HTM 770/4885MAPT 4411/4885ALDH1A1 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.